FIELD: medicine.
SUBSTANCE: invention relates to medical virology and to strain of influenza virus. Vaccine strain A/17/New York/15/5364 (H1N1) pdm09 is a reassortant obtained by crossing wild virus A/New York/61/2015 (H1N1) pdm09 with a cold-adapted temperature-sensitive virus A/Leningrad/134/17/57 (H2N2) – attenuation donor that is harmless to humans. Strain A/17/New York/15/5364 (H1N1) pdm09 is actively propagated in developing chick embryos at optimal temperature of 32 °C, is characterized by temperature sensitivity and cold tolerance and harmlessness for laboratory animals. Reassortant inherited the genes that encode surface antigens of hemagglutinin (HA) virus and neuraminidase (NA), from epidemic parental virus and remaining six genes encoding internal non-glycosylated proteins from the donor of attenuation.
EFFECT: presented solution can be used in practical public health for prevention of incidence of influenza in adults and children.
1 cl, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| VACCINE STRAIN OF INFLUENZA VIRUS A/17/SLOVENIA/2015/1121 (H1N1)PDM09 FOR PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2019 |
|
RU2724706C1 |
| VACCINE INFLUENZA VIRUS STRAIN A/17/Bolivia/2013/6585 (H1N1)pdm09 FOR PREPARING LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2015 |
|
RU2605314C1 |
| VACCINE STRAIN OF INFLUENZA VIRUS A/17/BRISBANE/2018/8175 (H1N1) PDM09 FOR PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2019 |
|
RU2735291C1 |
| VACCINE INFLUENZA VIRUS A/17/SOUTH AFRICA/2013/01 (H1N1)PDM09 FOR PRODUCTION OF LIVE INTRANASAL INFLUENZA VACCINE FOR ADULTS AND CHILDREN | 2016 |
|
RU2627188C1 |
| METHOD FOR ASSESSING THE REPRODUCTIVE ACTIVITY OF INFLUENZA VIRUSES IN A TRIVALENT AND QUADRIVALENT LIVE INFLUENZA VACCINE | 2019 |
|
RU2735293C1 |
| REASSORTANT STRAIN OF INFLUENZA VIRUS A/17/GUANGDONG-MAONAN/2019/211 (H1N1)PDM09 FOR PRODUCTION OF LIVE INTRANASAL INFLUENZA VACCINE FOR ADULTS AND CHILDREN | 2022 |
|
RU2793387C1 |
| REASSORTANT STRAIN OF INFLUENZA VIRUS A/17/VICTORIA/2019/276 (H1N1) PDM09 FOR THE PRODUCTION OF LIVE INTRANASAL INFLUENZA VACCINE FOR ADULTS AND CHILDREN | 2022 |
|
RU2783878C1 |
| REASSORTANT STRAIN OF INFLUENZA A/17/DARWIN/2018/154 (H1N1)PDM09 VIRUS FOR PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2023 |
|
RU2825670C1 |
| REASSORTANT STRAIN OF INFLUENZA A/17/IOWA/2018/5388 (H1N1)PDM09 VIRUS FOR PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2023 |
|
RU2825671C1 |
| ATTENUATED COLD-ADAPTED INFLUENZA VIRUS STRAIN A/PR/8/59/M2 (H1N1) APPLICABLE FOR VACCINAL INFLUENZA VIRUS STRAINS AS ATTENUATION DONOR, VACCINAL INFLUENZA VIRUS STRAINS A/59/M2/CALIFORNIA/66/2211 (H2N2) AND A/59/M2/TOKYO/67/22111 (H2N2) | 2011 |
|
RU2556833C2 |
